Similarly, a potential application for AD treatment was suggested for withaferin A (WA), a potent inhibitor of the Hsp90/Cdc37 interaction by regulation of LRRK2, like celastrol [138]. The gene discussed is HSP90AA1; the disease is Alzheimer disease.